Clinical Investigation of a DES (MiStent System) With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesions in Native Coronary Arteries

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary) ; Zotarolimus
Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Ischaemia
Focus Registrational; Therapeutic Use
Acronyms DESSOLVE-II
Sponsors Micell Technologies

09 Jan 2018 According to a Micell Technologies media release, 5-year results from DESSOLVE I and II trials have been published in EuroIntervention.
31 Oct 2016 Results presented at the 28th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference, as per Micell Technologies media release.
22 Mar 2016 According to the Micell Technologies media release, four-year data for this and DESSOLVE II study (CTP 191651) was presented at the 27th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com